ARCHIVES

Predicant, Correlogic executives contradict scientists’ claim that firms didn’t appear to compete.

This article is from The Cancer Letter archive.

Vol. 30 No. 26 | June 25, 2004

Download PDF Visit The Full Archive

Related Articles

Also von Eschenbach Role in Industry Program Raises New Concerns of Conflict of Interest.

November 22, 2006

Litton Awarded $342,618 For Frederick Fee

February 21, 1975

NCI, IOM Called To Congress to Explain Divergent Positions On Minority Research

January 29, 1999

FDA Breakthrough Designation Granted to Pfizer’s Palbociclib

April 26, 2013

NCI Program Develops Bioinformatics Tool To Design Cancer Drugs

September 13, 2002

Proof of principle needed before launching “big science” program, advisors say.

March 11, 2005